|
1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, et al: SEER Cancer Statistics Review,
1975–2011. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2011/2014
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lowenfels AB and Maisonneuve P: Can we
prevent pancreatic disease? Clin Gastroenterol Hepatol.
12:1645–1646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alsamarrai A, Das SL, Windsor JA and
Petrov MS: Factors that affect risk for pancreatic disease in the
general population: A systematic review and meta-analysis of
prospective cohort studies. Clin Gastroenterol Hepatol.
12:1635.e5–1644.e5; quiz e103. 2014. View Article : Google Scholar
|
|
9
|
Maisonneuve P and Lowenfels AB: Risk
factors for pancreatic cancer: A summary review of meta-analytical
studies. Int J Epidemiol. 44:186–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gronich N and Rennert G: Beyond
aspirin-cancer prevention with statins, metformin and
bisphosphonates. Nat Rev Clin Oncol. 10:625–642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosato V, Tavani A, Bosetti C, Pelucchi C,
Talamini R, Polesel J, Serraino D, Negri E and La Vecchia C:
Metabolic syndrome and pancreatic cancer risk: A case-control study
in Italy and meta-analysis. Metabolism. 60:1372–1378. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esposito K, Chiodini P, Colao A, Lenzi A
and Giugliano D: Metabolic syndrome and risk of cancer: A
systematic review and meta-analysis. Diabetes Care. 35:2402–2411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stocks T, Bjørge T, Ulmer H, Manjer J,
Häggström C, Nagel G, Engeland A, Johansen D, Hallmans G, Selmer R,
et al: Metabolic risk score and cancer risk: Pooled analysis of
seven cohorts. Int J Epidemiol. 44:1353–1363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong J, Robbins LA, Lugea A, Waldron RT,
Jeon CY and Pandol SJ: Diabetes, pancreatic cancer, and metformin
therapy. Front Physiol. 5:4262014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Gonzalez A Berrington, Sweetland S and
Spencer E: A meta-analysis of obesity and the risk of pancreatic
cancer. Br J Cancer. 89:519–523. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Larsson SC, Orsini N and Wolk A: Body mass
index and pancreatic cancer risk: A meta-analysis of prospective
studies. Int J Cancer. 120:1993–1998. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arslan AA, Helzlsouer KJ, Kooperberg C,
Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD,
Jacobs EJ, Lacroix AZ, et al: Anthropometric measures, body mass
index and pancreatic cancer: A pooled analysis from the Pancreatic
Cancer Cohort Consortium (PanScan). Arch Intern Med. 170:791–802.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiao L, de Gonzalez A Berrington, Hartge
P, Pfeiffer RM, Park Y, Freedman DM, Gail MH, Alavanja MC, Albanes
D, Freeman LE Beane, et al: Body mass index, effect modifiers, and
risk of pancreatic cancer: A pooled study of seven prospective
cohorts. Cancer Causes Control. 21:1305–1314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Genkinger JM, Spiegelman D, Anderson KE,
Bernstein L, van den Brandt PA, Calle EE, English DR, Folsom AR,
Freudenheim JL, Fuchs CS, et al: A pooled analysis of 14 cohort
studies of anthropometric factors and pancreatic cancer risk. Int J
Cancer. 129:1708–1717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aune D, Greenwood DC, Chan DS, Vieira R,
Vieira AR, Rosenblatt DA Navarro, Cade JE, Burley VJ and Norat T:
Body mass index, abdominal fatness and pancreatic cancer risk: A
systematic review and non-linear dose-response meta-analysis of
prospective studies. Ann Oncol. 23:843–852. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bethea TN, Kitahara CM, Sonderman J, Patel
AV, Harvey C, Knutsen SF, Park Y, Park SY, Fraser GE, Jacobs EJ, et
al: A pooled analysis of body mass index and pancreatic cancer
mortality in African Americans. Cancer Epidemiol Biomarkers Prev.
23:2119–2125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin Y, Fu R, Grant E, Chen Y, Lee JE,
Gupta PC, Ramadas K, Inoue M, Tsugane S, Gao YT, et al: Association
of body mass index and risk of death from pancreatic cancer in
Asians: Findings from the Asia Cohort Consortium. Eur J Cancer
Prev. 22:224–250. 2013. View Article : Google Scholar
|
|
23
|
Hori M, Takahashi M, Hiraoka N, Yamaji T,
Mutoh M, Ishigamori R, Furuta K, Okusaka T, Shimada K, Kosuge T, et
al: Association of pancreatic fatty infiltration with pancreatic
ductal adenocarcinoma. Clin Transl Gastroenterol. 5:e532014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rebours V, Gaujoux S, d'Assignies G,
Sauvanet A, Ruszniewski P, Levy P, Bedossa P, Paradis V and
Couvelard A: Obesity and fatty pancreatic infiltration are risk
factors for pancreatic precancerous lesions (PanIN). Clin Cancer
Res. 21:3522–3528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bao Y, Giovannucci EL, Kraft P, Stampfer
MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, et al:
A prospective study of plasma adiponectin and pancreatic cancer
risk in five US cohorts. J Natl Cancer Inst. 105:95–103. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bao Y and Michaud DS: Physical activity
and pancreatic cancer risk: A systematic review. Cancer Epidemiol
Biomarkers Prev. 17:2671–2682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O'Rorke MA, Cantwell MM, Cardwell CR,
Mulholland HG and Murray LJ: Can physical activity modulate
pancreatic cancer risk? a systematic review and meta-analysis. Int
J Cancer. 126:2957–2968. 2010.PubMed/NCBI
|
|
28
|
Behrens G, Jochem C, Schmid D, Keimling M,
Ricci C and Leitzmann MF: Physical activity and risk of pancreatic
cancer: A systematic review and meta-analysis. Eur J Epidemiol.
30:279–298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Melvin JC, Holmberg L, Rohrmann S, Loda M
and Van Hemelrijck M: Serum lipid profiles and cancer risk in the
context of obesity: Four meta-analyses. J Cancer Epidemiol.
2013:8238492013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Strohmaier S, Edlinger M, Manjer J, Stocks
T, Bjørge T, Borena W, Häggström C, Engeland A, Nagel G, Almquist
M, et al: Total serum cholesterol and cancer incidence in the
Metabolic syndrome and Cancer Project (Me-Can). PLoS One.
8:e542422013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen X, Zhou T and Chen M: Meta analysis
of the association of cholesterol with pancreatic carcinoma risk. J
BUON. 20:109–113. 2014. View Article : Google Scholar
|
|
32
|
Chen H, Qin S, Wang M, Zhang T and Zhang
S: Association between cholesterol intake and pancreatic cancer
risk: Evidence from a meta-analysis. Sci Rep. 5:82432015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen QW and Yao QY: Total fat consumption
and pancreatic cancer risk: A meta-analysis of epidemiologic
studies. Eur J Cancer Prev. 24:278–285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qin B, Xun P and He K: Fish or long-chain
(n-3) PUFA intake is not associated with pancreatic cancer risk in
a meta-analysis and systematic review. J Nutr. 142:1067–1073. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma YJ, Yu J, Xiao J and Cao BW: The
consumption of omega-3 polyunsaturated fatty acids improves
clinical outcomes and prognosis in pancreatic cancer patients: A
systematic evaluation. Nutr Cancer. 67:112–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bonovas S, Filioussi K and Sitaras NM:
Statins are not associated with a reduced risk of pancreatic cancer
at the population level, when taken at low doses for managing
hypercholesterolemia: Evidence from a meta-analysis of 12 studies.
Am J Gastroenterol. 103:2646–2651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bradley MC, Hughes CM, Cantwell MM and
Murray LJ: Statins and pancreatic cancer risk: A nested
case-control study. Cancer Causes Control. 21:2093–2100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chiu HF, Chang CC, Ho SC, Wu TN and Yang
CY: Statin use and the risk of pancreatic cancer: A
population-based case-control study. Pancreas. 40:669–672. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jacobs EJ, Newton CC, Thun MJ and Gapstur
SM: Long-term use of cholesterol-lowering drugs and cancer
incidence in a large United States cohort. Cancer Res.
71:1763–1771. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui X, Xie Y, Chen M, Li J, Liao X, Shen
J, Shi M, Li W, Zheng H and Jiang B: Statin use and risk of
pancreatic cancer: A meta-analysis. Cancer Causes Control.
23:1099–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Khurana V, Sheth A, Caldito G and Barkin
JS: Statins reduce the risk of pancreatic cancer in humans: A
case-control study of half a million veterans. Pancreas.
34:260–265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carey FJ, Little MW, Pugh TF, Ndokera R,
Ing H, Clark A, Dennison A, Metcalfe MS, Robinson RJ and Hart AR:
The differential effects of statins on the risk of developing
pancreatic cancer: A case-control study in two centres in the
United Kingdom. Dig Dis Sci. 58:3308–3312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Walker EJ, Ko AH, Holly EA and Bracci PM:
Statin use and risk of pancreatic cancer: Results from a large,
clinic-based case-control study. Cancer. 121:1287–1294. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chagpar RB, Martin RC, Ahmad SA, Kim HJ,
Rupp C, Weber S, Ebelhar A, Gilbert J, Brinkman A, Winslow E, et
al: Medically managed hypercholesterolemia and insulin-dependent
diabetes mellitus preoperatively predicts poor survival after
surgery for pancreatic cancer. J Gastrointest Surg. 15:551–557.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakai Y, Isayama H, Sasaki T, Mizuno S,
Sasahira N, Kogure H, Kawakubo K, Yamamoto N, Hirano K, Ijichi H,
et al: Clinical outcomes of chemotherapy for diabetic and
nondiabetic patients with pancreatic cancer: Better prognosis with
statin use in diabetic patients. Pancreas. 42:202–208. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jeon CY, Pandol SJ and Goodman MT:
Survival time in pancreatic cancer patients with metabolic syndrome
varies by use of insulin and statins. Cancer Res. 74:(Suppl 19).
21732014. View Article : Google Scholar
|
|
47
|
Mikulski SM, Viera A, Darzynkiewicz Z and
Shogen K: Synergism between a novel amphibian oocyte ribonuclease
and lovastatin in inducing cytostatic and cytotoxic effects in
human lung and pancreatic carcinoma cell lines. Br J Cancer.
66:304–310. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sumi S, Beauchamp RD, Townsend CM Jr,
Uchida T, Murakami M, Rajaraman S, Ishizuka J and Thompson JC:
Inhibition of pancreatic adenocarcinoma cell growth by lovastatin.
Gastroenterology. 103:982–989. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ura H, Obara T, Nishino N, Tanno S,
Okamura K and Namiki M: Cytotoxicity of simvastatin to pancreatic
adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res.
85:633–638. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Müller C, Bockhorn AG, Klusmeier S, Kiehl
M, Roeder C, Kalthoff H and Koch OM: Lovastatin inhibits
proliferation of pancreatic cancer cell lines with mutant as well
as with wild-type K-ras oncogene but has different effects on
protein phosphorylation and induction of apoptosis. Int J Oncol.
12:717–723. 1998.PubMed/NCBI
|
|
51
|
Kamiński R, Kozar K, Kopeć M, Basak G,
Skierski JS, Koronkiewicz M, Jakóbisiak M and Gołab J: Discussion
on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors
reduce human pancreatic cancer cell invasion and metastasis.
Gastroenterology. 123:17472002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kusama T, Mukai M, Iwasaki T, Tatsuta M,
Matsumoto Y, Akedo H and Nakamura H: Inhibition of epidermal growth
factor-induced RhoA translocation and invasion of human pancreatic
cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase
inhibitors. Cancer Res. 61:4885–4891. 2001.PubMed/NCBI
|
|
53
|
Kusama T, Mukai M, Iwasaki T, Tatsuta M,
Matsumoto Y, Akedo H, Inoue M and Nakamura H:
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce
human pancreatic cancer cell invasion and metastasis.
Gastroenterology. 122:308–317. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bocci G, Fioravanti A, Orlandi P,
Bernardini N, Collecchi P, Del Tacca M and Danesi R: Fluvastatin
synergistically enhances the antiproliferative effect of
gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J
Cancer. 93:319–330. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Issat T, Nowis D, Legat M, Makowski M,
Klejman MP, Urbanski J, Skierski J, Koronkiewicz M, Stoklosa T,
Brzezinska A, et al: Potentiated antitumor effects of the
combination treatment with statins and pamidronate in vitro and in
vivo. Int J Oncol. 30:1413–1425. 2007.PubMed/NCBI
|
|
56
|
Liao J, Chung YT, Yang AL, Zhang M, Li H,
Zhang W, Yan L and Yang GY: Atorvastatin inhibits pancreatic
carcinogenesis and increases survival in
LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. Mol Carcinog.
52:739–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fendrich V, Sparn M, Lauth M, Knoop R,
Plassmeier L, Bartsch DK and Waldmann J: Simvastatin delay
progression of pancreatic intraepithelial neoplasia and cancer
formation in a genetically engineered mouse model of pancreatic
cancer. Pancreatology. 13:502–507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mohammed A, Qian L, Janakiram NB,
Lightfoot S, Steele VE and Rao CV: Atorvastatin delays progression
of pancreatic lesions to carcinoma by regulating PI3/AKT signaling
in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer. 131:1951–1962. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mistafa O and Stenius U: Statins inhibit
Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Biochem Pharmacol. 78:1115–1126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ding N, Cui XX, Gao Z, Huang H, Wei X, Du
Z, Lin Y, Shih WJ, Rabson AB, Conney AH, et al: A triple
combination of atorvastatin, celecoxib and tipifarnib strongly
inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Int J Oncol. 44:2139–2145. 2014.PubMed/NCBI
|
|
61
|
Gbelcová H, Svéda M, Laubertová L, Varga
I, Vítek L, Kolář M, Strnad H, Zelenka J, Böhmer D and Ruml T: The
effect of simvastatin on lipid droplets accumulation in human
embryonic kidney cells and pancreatic cancer cells. Lipids Health
Dis. 12:1262013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ishikawa S, Nagai Y, Masuda T, Koga Y,
Nakamura T, Imamura Y, Takamori H, Hirota M, Funakosi A, Fukushima
M and Baba H: The role of oxysterol binding protein-related protein
5 in pancreatic cancer. Cancer Sci. 101:898–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Souchek JJ, Baine MJ, Lin C, Rachagani S,
Gupta S, Kaur S, Lester K, Zheng D, Chen S, Smith L, et al:
Unbiased analysis of pancreatic cancer radiation resistance reveals
cholesterol biosynthesis as a novel target for radiosensitisation.
Br J Cancer. 111:1139–1149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Maione F, Oliaro-Bosso S, Meda C, Di
Nicolantonio F, Bussolino F, Balliano G, Viola F and Giraudo E: The
cholesterol biosynthesis enzyme oxidosqualene cyclase is a new
target to impair tumour angiogenesis and metastasis dissemination.
Sci Rep. 5:90542015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider
M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, et al: Role of
fatty acid synthase in gemcitabine and radiation resistance of
pancreatic cancers. Int J Biochem Mol Biol. 2:89–98.
2011.PubMed/NCBI
|
|
66
|
Hussein D and Mo H:
d-δ-Tocotrienol-mediated suppression of the proliferation of human
PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.
Pancreas. 38:e124–e136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Shin-Kang S, Ramsauer VP, Lightner J,
Chakraborty K, Stone W, Campbell S, Reddy SA and Krishnan K:
Tocotrienols inhibit AKT and ERK activation and suppress pancreatic
cancer cell proliferation by suppressing the ErbB2 pathway. Free
Radic Biol Med. 51:1164–1174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guillaumond F, Bidaut G, Ouaissi M,
Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet
O, et al: Cholesterol uptake disruption, in association with
chemotherapy, is a promising combined metabolic therapy for
pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 112:2473–2478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Menter DG, Ramsauer VP, Harirforoosh S,
Chakraborty K, Yang P, Hsi L, Newman RA and Krishnan K:
Differential effects of pravastatin and simvastatin on the growth
of tumor cells from different organ sites. PLoS One. 6:e288132011.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gbelcová H, Lenícek M, Zelenka J, Knejzlík
Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T
and Vítek L: Differences in antitumor effects of various statins on
human pancreatic cancer. Int J Cancer. 122:1214–1221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hong JY, Nam EM, Lee J, Park JO, Lee SC,
Song SY, Choi SH, Heo JS, Park SH, Lim HY, et al: Randomized
double-blinded, placebo-controlled phase II trial of simvastatin
and gemcitabine in advanced pancreatic cancer patients. Cancer
Chemother Pharmacol. 73:125–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Swierczynski J, Hebanowska A and
Sledzinski T: Role of abnormal lipid metabolism in development,
progression, diagnosis and therapy of pancreatic cancer. World J
Gastroenterol. 20:2279–2303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Søreide K and Sund M:
Epidemiological-molecular evidence of metabolic reprogramming on
proliferation, autophagy and cell signaling in pancreas cancer.
Cancer Lett. 356:281–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
